Print

The Medicines Company (MDCO) Release: British Medical Leaders Report Results of Global Heart Attack Study  
6/16/2011 9:58:19 AM

OXFORDSHIRE, ENGLAND--(Marketwire - June 16, 2011) - Professor Stuart J. Pocock of the London School of Hygiene and Tropical Medicine was lead statistician and co-author of a heart attack study published this week by The Lancet, a London-based peer reviewed medical journal.

The article reviewed the final three year results of a clinical trial called HORIZONS-AMI that was conducted globally in 3,602 heart attack patients, 102 of whom were treated in the United Kingdom. The authors span three continents, six countries and five native languages.

"Heart attacks continue to be the most frequent killer in the world," said Dr. Clive Meanwell, entrepreneur, health science innovator and chief executive of The Medicines Company, which provided research grant support for the study. "Investigators -- including experts from the United Kingdom -- have demonstrated with this study that global multidisciplinary collaboration enables a potential step forward in healthcare."

HORIZONS-AMI findings affected revisions to heart attack treatment guidelines published by the European Society for Cardiology (ESC) and the British Cardiovascular Society in 2010. In England and Wales, according to the Office for National Statistics, about 31,283 people die from heart attacks in 2007.

The Lancet article is the final of primary HORIZONS-AMI analyses published in major peer reviewed journals at 30 days, 1 year, 2 years and now 3 years of patient follow-up after their procedure. There have also been more than 60 secondary analyses published examining results in patient sub-populations. The latest was an analysis of patients who had drug therapies switched in the course of their treatment and was published in the Journal of the American College of Cardiology last week.


Contact:
Michael Mitchell
The Medicines Company
+973-290-6000
corporate.communications@themedco.com